“Move fast and break things” becomes ethically dangerous in regulated industries when speed outruns evidence, safety testing, legal duties, and accountability. In aviation, healthcare, finance, transportation, and pharmaceuticals, “breaking things” can mean harming patients, passengers, customers, markets, and public trust.
This article explains where the mantra came from, why it fails in regulated sectors, and how you can build fast-moving innovation without treating compliance as a speed bump. You’ll see what Boeing, Theranos, Volkswagen, Uber, FTX, and Aduhelm reveal about speed-first decision-making, then learn practical ways to move faster without breaking trust.
What Does “Move Fast And Break Things” Actually Mean?
It means shipping, testing, and changing quickly, even if mistakes happen along the way. The phrase became famous through Facebook’s early engineering culture, then spread into startup thinking as shorthand for speed, disruption, and tolerance for failure.
In software, the phrase once made a certain kind of operational sense. If a social feature failed, a team could roll it back, patch the bug, and learn from user behavior. The cost of failure was often downtime, user frustration, or a damaged product metric. That’s still serious, but it’s different from a medical device giving unreliable results or an aircraft system behaving in a way pilots don’t expect.
Facebook later moved away from the original slogan and adopted “move fast with stable infra,” a telling shift. The change acknowledged that speed without stability creates technical debt, operational risk, and user harm. For regulated industries, that lesson lands even harder. Stability isn’t a polish item; it’s part of the product’s moral and legal foundation.
When you apply the phrase to regulated industries, the meaning changes. You’re no longer breaking a feature or a workflow. You may be breaking a safety case, a clinical validation process, a financial control, a transportation rule, or an emissions standard. That’s where the ethical line appears.
Why Does This Mantra Clash With Regulated Industries?
The mantra clashes with regulated industries because these sectors are designed around controlled proof, not public trial and error. You can still innovate quickly, but you can’t use customers, patients, passengers, or communities as your quality assurance system.
Regulated sectors exist because failure carries public consequences. Aviation rules are built around accident prevention. Healthcare rules are built around patient safety and reliable evidence. Financial controls are built to protect customers, markets, and trust. Environmental rules are built to limit harm that may not be visible to the buyer at the time of sale.
Agile product development is useful when it helps teams learn faster inside safe boundaries. It becomes dangerous when leaders confuse iteration with exemption. A minimum viable product in a consumer app can be rough around the edges. A minimum viable diagnostic test, trading platform, aircraft feature, or emissions-control system needs proof that the “minimum” still protects people.
You also need to recognize ethical debt. Like technical debt, it builds when a company chooses short-term progress over disciplined design, documentation, testing, and review. The bill arrives later through recalls, investigations, lawsuits, shutdowns, lost licenses, and public distrust. In regulated industries, that bill can arrive with human cost attached.
Can Startups Move Fast Without Breaking The Law?
Yes, startups can move fast without breaking the law by narrowing experiments, validating claims early, documenting decisions, and designing compliance into the product from the start. Speed becomes safer when your team defines what can be tested freely and what must pass formal review before release.
The mistake many founders make is treating regulation as an external obstacle. In practice, regulation is part of the product environment. If you’re building in healthcare, aviation, energy, mobility, banking, insurance, or pharmaceuticals, your product is not finished when the code works. It’s finished when the evidence, process, controls, disclosures, and monitoring support the claim you’re making.
A faster path starts with classification. You need to know whether you’re making a wellness claim, a diagnostic claim, a safety claim, a financial claim, or an operational claim that affects regulated activity. Each claim changes the proof you need. The earlier you map that claim, the less likely you are to rebuild your product after legal, clinical, safety, or compliance teams raise concerns.
Controlled pilots can also keep momentum high. A limited test with defined users, monitored outcomes, rollback plans, and clear disclosures gives you learning without pretending the product is ready for unrestricted use. That’s different from launching first and asking permission later. In regulated sectors, permission is often part of the safety system.
How Did Boeing Show The Cost Of A Speed-First Culture?
The Boeing 737 MAX crisis showed how schedule pressure, flawed assumptions, weak oversight, and poor transparency can turn speed into catastrophe. Two crashes killed 346 people, and official investigations found deep failures in design, certification, and company culture.
The Maneuvering Characteristics Augmentation System, known as MCAS, became central to the crisis. Investigators found that the aircraft’s certification process did not give the system the scrutiny it needed. The U.S. House Committee on Transportation and Infrastructure described problems including a “culture of concealment” and “grossly insufficient oversight.” Those findings matter because they show that the ethical failure was not limited to one technical component.
When you work in aviation, speed must answer to safety evidence. A design change needs a safety case, pilot training analysis, failure-mode review, and clear communication with regulators and operators. Any culture that rewards schedule protection over risk disclosure puts engineers, pilots, passengers, and the company itself in danger. The Boeing case is now a warning about what happens when internal pressure bends safety process.
The legal and financial fallout was severe. Boeing agreed to pay more than $2.5 billion through a U.S. Department of Justice settlement tied to the 737 MAX matter. The deeper cost was public trust. Once passengers question whether a company placed speed above safety, recovery takes far longer than any product cycle.
What Did Theranos Reveal About “Fake It Till You Make It” In Healthcare?
Theranos showed that “fake it till you make it” becomes unacceptable when patients and clinicians rely on your claims for health decisions. The company promoted rapid blood testing without proving that its technology could deliver reliable results at the scale it promised.
Healthcare is unforgiving because inaccurate information can send care in the wrong direction. A lab result influences follow-up testing, medication choices, specialist referrals, and patient anxiety. If the underlying test is unreliable, the harm spreads through the care process. That’s why clinical validation is not red tape; it’s part of patient protection.
Regulatory inspection findings reported serious concerns about Theranos lab practices, including risks to patient health and safety. Later reporting found that more than 1 million test results were corrected or voided. Elizabeth Holmes was convicted of fraud, and the company ultimately dissolved. The case stands as one of the clearest examples of startup storytelling outrunning scientific proof.
The lesson for you is direct: don’t sell a regulated capability before the evidence exists. You can build prototypes, run internal tests, seek expert review, and collect data. You can’t make medical claims as if your future product already works. In healthcare, ambition doesn’t substitute for validation.
What Other Failures Show The Same Pattern?
Volkswagen, Uber, FTX, and Aduhelm show different versions of the same failure: speed or market pressure moving ahead of controls, evidence, or lawful process. The details differ, but the pattern is familiar.
Volkswagen’s emissions scandal involved defeat devices used to cheat emissions tests. The company’s misconduct placed market performance and product claims ahead of environmental rules. Penalties, settlements, and buybacks exceeded $30 billion. For you, the lesson is that regulatory cheating can look like a shortcut until it becomes a company-defining crisis.
Uber’s early expansion offers a different model of friction with rules. The company entered markets quickly and often fought local transportation systems after launching. Its “Greyball” program, exposed by The New York Times, was used to evade authorities in some locations. That tactic damaged trust because it treated regulators as enemies to outmaneuver rather than public bodies to engage.
FTX showed how speed without financial controls can collapse trust at scale. Sam Bankman-Fried was convicted of fraud after the crypto exchange failed amid a massive funding gap. Aduhelm raised a separate concern: pressure for faster access to treatment can collide with disputes over evidence. In each case, the lesson is not “move slowly.” The lesson is to move at the speed your proof and controls can support.
What Ethical Models Should Guide Innovation In Regulated Industries?
The best ethical models combine risk management, precaution, stakeholder responsibility, and controlled experimentation. You need a decision system that rewards evidence, transparency, and speed within guardrails.
The precautionary principle is useful when harm could be serious, widespread, or hard to reverse. It asks you to slow down enough to understand danger before scaling exposure. That does not mean blocking innovation by default. It means matching the burden of proof to the possible harm.
ISO 31000 gives organizations a risk management standard that can support faster decisions without guesswork. It encourages structured identification, assessment, treatment, monitoring, and communication of risk. For a regulated startup, that discipline can prevent scattered decisions across product, legal, engineering, clinical, finance, and compliance teams.
Regulatory sandboxes can also help. A sandbox allows controlled testing under regulator supervision, often with limits on users, claims, duration, and exposure. That model is useful because it creates space to learn without pretending early-stage systems are ready for open-ended public use. For founders, the practical takeaway is simple: design the experiment so failure stays contained.
How Do You Build A Culture That Moves Fast And Fixes Fast?
You build it by making safety, evidence, and correction part of daily work instead of late-stage approval gates. A good culture does not ask teams to choose between speed and responsibility; it defines where speed is allowed and where proof is mandatory.
Start with decision rights. Engineers, clinicians, safety specialists, compliance leaders, and product owners need clear authority to stop a release when evidence is weak. If only growth leaders can say yes and everyone else can merely advise, the system is tilted. Regulated innovation needs real stop signals, not ceremonial review.
Build feedback loops that surface problems early. Internal reporting channels, protected escalation paths, and psychological safety help employees raise concerns before outsiders discover them. Theranos, Boeing, and Volkswagen all show how damaging it can be when people inside an organization feel pressure to stay quiet or when warnings fail to change decisions.
You also need post-release discipline. Monitoring should track safety events, customer complaints, accuracy issues, system drift, and compliance exceptions. Fixing fast means acknowledging problems, limiting exposure, correcting the system, and updating claims. It does not mean hiding defects until a public scandal forces action.
What Should Regulators Do Without Slowing Progress To A Crawl?
Regulators can support innovation by giving clearer rules, faster guidance, controlled testing paths, and outcome-based requirements without lowering safety expectations. Good regulation should reduce uncertainty, not reward delay.
Startups often move around regulators when the path feels unclear or too slow. That frustration is real, especially in fields where new technology doesn’t fit older categories. Regulators can help by publishing practical guidance, creating early consultation routes, and explaining what evidence is needed at each stage. Clarity can speed responsible teams and expose reckless ones.
Outcome-based rules can also help when technology changes faster than prescriptive rules. If a rule defines the safety, accuracy, privacy, environmental, or financial outcome required, companies can innovate toward that target. The regulator still enforces the bar. The company gets room to choose the method.
Public agencies should also expand controlled testing options where appropriate. Sandboxes, limited approvals, staged rollouts, and monitored pilots can move promising products forward without allowing open-ended risk. The aim is not frictionless innovation. The aim is faster learning with smaller blast radius.
What Are The Biggest Ethical Failures Linked To This Mantra?
- Boeing 737 MAX: 346 deaths
- Theranos: unsafe lab practices
- Volkswagen: emissions cheating
- Uber: regulator evasion
- FTX: weak financial controls
Move Fast, But Don’t Break Trust
The ethics of “move fast and break things” in regulated industries comes down to one hard rule: the faster you move, the better your guardrails need to be. Boeing shows what happens when safety review loses authority. Theranos shows the danger of selling proof before proof exists. Volkswagen, Uber, FTX, and Aduhelm show that pressure to win markets can distort judgment across very different sectors. If you’re building in a regulated field, speed is still valuable, but trust is the asset you can’t patch after release.
References
- TechCrunch: Facebook’s Shift To “Move Fast With Stable Infra”
- U.S. House Committee On Transportation And Infrastructure: Boeing 737 MAX Investigation
- U.S. Department Of Justice: Boeing 737 MAX Settlement
- The Wall Street Journal: Theranos Blood Testing Investigation
- The Wall Street Journal: Theranos Voided Tests Reporting
- The New York Times: Uber Greyball Program
- Environmental Protection Agency: Volkswagen Violations
- Violation Tracker: Corporate Penalties Database
- STAT News: Aduhelm Approval Controversy
- House Committee On Oversight And Reform: Aduhelm Approval Report
- International Organization For Standardization: ISO 31000 Risk Management Guidelines
- Harvard Business Review: The Precautionary Principle And Innovation
- MIT Technology Review: We Need To Fix The Way We Innovate
Alex Clug is a global entrepreneur and investor with 25+ years building and scaling ventures in medical robotics, telecommunications, mining, and private equity. He currently leads The Dolphin Group, advising early-stage and cross-border companies in robotics, fintech, natural resources, and other innovation-driven industries.